ClinicalTrials.govpublic full text
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
gastric cancer, gastroesophageal junction adenocarcinoma, bemarituzumab, fgfr2b overexpression, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 806247
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.